NASDAQ:GDRX GoodRx (GDRX) Stock Price, News & Analysis → Elon Musk: THIS will be bigger than Tesla (From Paradigm Press) (Ad) Free GDRX Stock Alerts $8.51 -0.27 (-3.08%) (As of 06/14/2024 08:51 PM ET) Add Compare Share Share Today's Range$8.44▼$8.7650-Day Range$6.50▼$8.9152-Week Range$4.14▼$9.37Volume876,700 shsAverage Volume1.51 million shsMarket Capitalization$3.19 billionP/E RatioN/ADividend YieldN/APrice Target$9.32 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get GoodRx alerts: Email Address GoodRx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.55 Rating ScoreUpside/Downside9.5% Upside$9.32 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.18Based on 20 Articles This WeekInsider TradingN/AProj. Earnings Growth47.06%From $0.17 to $0.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector776th out of 913 stocksData Processing & Preparation Industry46th out of 57 stocks 2.3 Analyst's Opinion Consensus RatingGoodRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on 12 buy ratings, 7 hold ratings, and 1 sell rating.Amount of Analyst CoverageGoodRx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about GoodRx's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for GDRX. Previous Next 0.0 Dividend Strength Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDRX. Previous Next 1.8 News and Social Media Coverage News SentimentGoodRx has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for GoodRx this week, compared to 6 articles on an average week.Search InterestOnly 12 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.17% of the stock of GoodRx is held by insiders.Percentage Held by Institutions63.77% of the stock of GoodRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about GoodRx's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GoodRx are expected to grow by 47.06% in the coming year, from $0.17 to $0.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is -850.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is -850.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioGoodRx has a PEG Ratio of 3.97. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 4.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about GoodRx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Warrior Life(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” Most citizens don’t… but according to my friend (and best-selling survival author), Jeff, even the hardcore “preppers” who cherish their bug-out bags are doing it all wrong!All the details are right here… About GoodRx Stock (NASDAQ:GDRX)GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.Read More GDRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDRX Stock News HeadlinesJune 16 at 10:15 AM | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitJune 14 at 2:24 PM | businesswire.comRosen Law Firm Urges GoodRx Holdings, Inc. (GDRX) Stockholders with Large Losses to Contact the Firm for Information About Their RightsJune 14 at 5:45 AM | prnewswire.comInvestors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your Rights - GDRXJune 13, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against GoodRx Holdings, Inc. - GDRXJune 12, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitJune 12, 2024 | globenewswire.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxJune 11, 2024 | businesswire.comGDRX INVESTOR ALERT: Kirby McInerney LLP Notifies GoodRx Holdings, Inc. Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitJune 11, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitJune 11, 2024 | globenewswire.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in GoodRx Holdings, Inc. with Losses to Contact the FirmJune 11, 2024 | americanbankingnews.comGoodRx (NASDAQ:GDRX) Price Target Increased to $9.50 by Analysts at Morgan StanleyJune 10, 2024 | globenewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important June 21 Deadline in Securities Class Action – GDRXJune 10, 2024 | prnewswire.comROSEN, TOP RANKED GLOBAL COUNSEL, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GDRXJune 10, 2024 | globenewswire.comGOODRX HOLDINGS, INC. (NASDAQ: GDRX) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against GoodRx Holdings, Inc.June 10, 2024 | prnewswire.comDeadline in 11 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)June 10, 2024 | prnewswire.comClass Action Filed Against GoodRx Holdings, Inc. (GDRX) Seeking Recovery for Investors - Contact The Gross Law FirmJune 10, 2024 | globenewswire.comGDRX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 9, 2024 | businesswire.comGoodRx Holdings, Inc. NASDAQ: GDRX: Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPJune 8, 2024 | americanbankingnews.comAnalysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Target Price at $9.11June 7, 2024 | prnewswire.comGDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud LawsuitJune 7, 2024 | globenewswire.comContact Levi & Korsinsky by June 21, 2024 Deadline to Join Class Action Against GoodRx Holdings, Inc. (GDRX)June 6, 2024 | globenewswire.comContact The Gross Law Firm by June 21, 2024 Deadline to Join Class Action Against GoodRx Holdings, Inc. (GDRX)June 6, 2024 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of GoodRxJune 6, 2024 | prnewswire.comLevi & Korsinsky Reminds GoodRx Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 21, 2024 - GDRXJune 5, 2024 | prnewswire.comGoodRx Holdings, Inc. NASDAQ: GDRX: Investors: June 21, 2024 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLPJune 5, 2024 | globenewswire.comGDRX STOCKHOLDERS – Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the GoodRx Holdings, Inc. Class ActionSee More Headlines Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/16/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Data processing & preparation Sub-IndustryN/A Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees694Year FoundedN/APrice Target and Rating Average Stock Price Target$9.32 High Stock Price Target$16.00 Low Stock Price Target$4.50 Potential Upside/Downside+9.5%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($0.01) Trailing P/E RatioN/A Forward P/E Ratio50.06 P/E Growth3.97Net Income$-8,870,000.00 Net Margins-0.86% Pretax Margin-7.70% Return on Equity3.45% Return on Assets1.70% Debt Debt-to-Equity Ratio1.02 Current Ratio6.29 Quick Ratio6.29 Sales & Book Value Annual Sales$750.27 million Price / Sales4.26 Cash Flow$0.41 per share Price / Cash Flow20.61 Book Value$1.93 per share Price / Book4.41Miscellaneous Outstanding Shares375,200,000Free Float359,559,000Market Cap$3.19 billion OptionableOptionable Beta1.40 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Trevor Bezdek (Age 46)Co-founder & Chairman Comp: $537kMr. Douglas Joseph Hirsch (Age 53)Co-founder, Chief Mission Officer & Director Comp: $507.29kMr. Karsten Ian Voermann (Age 54)CFO & Principal Financial Officer Comp: $693.69kMr. Romin Nabiey (Age 36)Chief Accounting Officer & Principal Accounting Officer Comp: $516kMr. Scott W. Wagner (Age 53)Interim CEO & Principal Operating Officer Mr. Mike WalshPresident & Executive VP of Prescription MarketplaceMs. Whitney NotaroVice President of Investor RelationsMs. Gracye ChengGeneral Counsel & SecretaryMr. Andrew Slutsky (Age 37)Chief Marketing Officer Comp: $864.8kMs. Vina M. Leite (Age 54)Chief People Officer More ExecutivesKey CompetitorsDada NexusNASDAQ:DADAZendeskNYSE:ZENToastNYSE:TOSTRedditNYSE:RDDTGlobantNYSE:GLOBView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 21,800 shares on 5/17/2024Ownership: 0.000%Beacon Capital Management LLCBought 4,000 shares on 5/17/2024Ownership: 0.001%California State Teachers Retirement SystemBought 3,444 shares on 5/16/2024Ownership: 0.018%Bayesian Capital Management LPSold 27,100 shares on 5/16/2024Ownership: 0.004%EntryPoint Capital LLCBought 11,548 shares on 5/14/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions GDRX Stock Analysis - Frequently Asked Questions Should I buy or sell GoodRx stock right now? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GDRX shares. View GDRX analyst ratings or view top-rated stocks. What is GoodRx's stock price target for 2024? 20 brokers have issued 1 year price targets for GoodRx's stock. Their GDRX share price targets range from $4.50 to $16.00. On average, they predict the company's stock price to reach $9.32 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts. How have GDRX shares performed in 2024? GoodRx's stock was trading at $6.70 at the start of the year. Since then, GDRX stock has increased by 27.0% and is now trading at $8.51. View the best growth stocks for 2024 here. When is GoodRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our GDRX earnings forecast. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) released its quarterly earnings results on Thursday, May, 9th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.04 by $0.01. The firm had revenue of $197.88 million for the quarter, compared to analyst estimates of $196.20 million. GoodRx had a positive trailing twelve-month return on equity of 3.45% and a negative net margin of 0.86%. What ETFs hold GoodRx's stock? ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include Fidelity Digital Health ETF (FDHT), WisdomTree Growth Leaders Fund (PLAT), Global X Telemedicine & Digital Health ETF (EDOC) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF). What guidance has GoodRx issued on next quarter's earnings? GoodRx updated its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $800.0 million-$810.0 million, compared to the consensus revenue estimate of $801.0 million. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX). When did GoodRx IPO? GoodRx (GDRX) raised $900 million in an initial public offering (IPO) on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays served as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. Who are GoodRx's major shareholders? GoodRx's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.05%), Assenagon Asset Management S.A. (0.26%), Picton Mahoney Asset Management (0.12%), GSA Capital Partners LLP (0.06%), Susquehanna Portfolio Strategies LLC (0.05%) and Mirae Asset Global Investments Co. Ltd. (0.05%). Insiders that own company stock include Abdiel Capital Management, Llc, Agnes Rey-Giraud, Andrew Slutsky, Babak Azad, Bansi Nagji, Douglas Joseph Hirsch, Idea Men, Llc, Karsten Voermann, Scott Wagner and Trevor Bezdek. View institutional ownership trends. How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GDRX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GoodRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.